drugset / Trial / NCT02568683
Safety and Efficacy of Entospletinib (ENTO [GS-9973]) Combined With Vincristine (VCR) in Adult Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)
Non-randomizedSequentialOpen-labelTreatment
Summary
The primary objective of this study is to evaluate the safety of ENTO with VCR in participants with relapsed or refractory B-cell NHL.
Timeline
- Start
- 2016-02-11
- Primary completion
- 2016-10-03
- Completion
- 2017-06-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Entospletinib | Small molecule | — | Oral |
| Subject | Vincristine | Small molecule | — | Intravenous |